Back to top
more

HeartBeam (BEAT)

(Delayed Data from NSDQ)

$2.36 USD

2.36
129,698

-0.05 (-2.07%)

Updated Nov 12, 2024 04:00 PM ET

After-Market: $2.35 -0.01 (-0.42%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (46 out of 249)

Industry: Medical Info Systems

Zacks News

The Zacks Analyst Blog Highlights: Banner, Amazon.com, BJ's, athenahealth and BioTelemetry

The Zacks Analyst Blog Highlights: Banner, Amazon.com, BJ's, athenahealth and BioTelemetry

    Tirthankar Chakraborty headshot

    Bull Run Set to Become the Longest in History: 5 Winners

    The current bull market in U.S. stocks is about to become the longest on record, and optimistic analysts are predicting that it has miles to go before it rests.

      Should First Trust Small Cap Growth AlphaDEX Fund (FYC) Be on Your Investing Radar?

      Style Box ETF report for FYC

        Top Ranked Momentum Stocks to Buy for August 7th

        Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 7th:

          Options Traders Expect Huge Moves in BioTelemetry (BEAT) Stock

          BioTelemetry (BEAT) needs investors to pay close attention to the stock based on moves in the options market lately.

            Zacks.com featured highlights include: BioTelemetry, Fair Isaac, Comerica and Blue Hills

            Zacks.com featured highlights include: BioTelemetry, Fair Isaac, Comerica and Blue Hills

              Tirthankar Chakraborty headshot

              4 Top Stocks to Buy on Blockbuster Earnings Growth

              We shortlist four solid stocks that have striking earnings growth and positive estimate revisions.

                Top Ranked Momentum Stocks to Buy for July 31st

                Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 31st:

                  Brian Bolan headshot

                  Elevate Credit (ELVT) and BioTelemetry (BEAT) Are Aggressive Growth Stocks

                  A look at two stocks for your aggressive growth stock radar.

                    NovoCure (NVCR) Catches Eye: Stock Jumps 7.4%

                    NovoCure (NVCR) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

                      Biocept, Inc. (BIOC) Soars: Stock Adds 9.8% in Session

                      Biocept (BIOC) was a big mover last session, as the company saw its shares rise more than 9% on Friday amid huge volumes.

                        Natera (NTRA) Catches Eye: Stock Jumps 6.3%

                        Natera (NTRA) shares rose more than 6% in the last trading session, amid huge volumes.

                          BioTelemetry (BEAT) Beats Q4 Earnings and Revenue Estimates

                          BioTelemetry (BEAT) sees strong Q4 results, courtesy of solid acquisitions and promising performance by the MCT platform.

                            BioTelemetry's (BEAT) Telcare Unit Collaborates With Onduo

                            BioTelemetry (BEAT) progresses with deals to strengthen hold in the high-potential diabetes care market.

                              BioTelemetry Ties Up With Apple, Grows in Cardiac Monitoring

                              BioTelemetry (BEAT) is consistently trying to improve its position in the cardiac monitoring and diagnostic services space.

                                BioTelemetry (BEAT) Q3 Earnings Miss, Revenues Meet Estimates

                                A decline in gross and operating margin was a major drag for BioTelemetry (BEAT) in the third quarter.

                                  BioTelemetry, Royal Gold, Microsoft and Amazon highlighted as Zacks Bull and Bear of the Day

                                  BioTelemetry, Royal Gold, Microsoft and Amazon highlighted as Zacks Bull and Bear of the Day

                                    Kevin Cook headshot

                                    Bull of the Day: BioTelemetry (BEAT)

                                    This small veteran in the "connected health" space doesn't need to beat Apple to win

                                      PAREXEL's Acquisition by Pamplona Approved by Shareholders

                                      The long-awaited PAREXEL (PRXL) acquisition by Pamplona Capital Management finally receives shareholders' approval. Moreover, the company plans to go private post-acquisition.

                                        Here's Why Mazor Robotics (MZOR) Stock Is Worth a Bet Now

                                        The market is upbeat about Mazor Robotics' (MZOR) recent CE Mark approval for Mazor X Surgical Assurance platform.

                                          Here's Why You Should Invest in Orthofix International Now

                                          Orthofix (OFIX) rides high on strength in Biologics and Spine Fixation.

                                            Zacks.com featured highlights include JA Solar Holdings, BioTelemetry, Arista Networks, Owens Corning and Aaron's

                                            Zacks.com featured highlights include JA Solar Holdings, BioTelemetry, Arista Networks, Owens Corning and Aaron's

                                              Here's Why You Should Bet on BioTelemetry (BEAT) Stock Now

                                              BioTelemetry's (BEAT) consistent efforts in product innovation through research and development buoy optimism. Also, the recent acquisition instills confidence in investors.

                                                5 Momentum Stocks Powered by Driehaus Strategy

                                                One of the most widely used investment approaches for those interested in momentum stocks is the Driehaus strategy

                                                  Can BioTelemetry (BEAT) Run Higher on Strong Earnings Estimate Revisions?

                                                  BioTelemetry (BEAT) is seeing solid earnings estimate revisions, and the stock is showing decent short-term momentum as well.